Cheng D, Zhu X, Gillespie DG, Jackson EK. Role of RACK1 in the differential proliferative effects of neuropeptide Y 1-36 and peptide YY and PYY1-36 stimulated proliferation. In SHR PGVSMCs, inhibitors of the G i/phospholipase C/PKC pathway (a pathway known to be organized by RACK1) attenuated the ability of NPY 1-36 to stimulate the proliferation of SHR PGVSMCs. Our results suggest that RACK1 modulates the ability of PGVSMCs to respond to the proliferative actions of NPY 1-36 and PYY1-36 and differences in RACK1 levels/ localization account for, in part, differential proliferative responses to NPY 1-36 and PYY1-36 in SHR vs. WKY PGVSMCs. Because dipeptidyl peptidase IV inhibitors increase NPY 1-36 and PYY1-36 levels, our findings have implications for the use of such drugs in diabetic patients.
NEUROPEPTIDE Y1-36 (NPY1-36) and peptide YY (PYY ) are members of the pancreatic polypeptide-fold (PP-fold) family (6) . Importantly, the kidney is likely exposed to biologically active levels of PP-fold peptides because 1) renal sympathetic varicosities release NPY in response to CNS-mediated activation of renal sympathetic nerves (13) ; 2) NPY 1-36 is made by renal epithelial cells and released into the renal interstitium (22) ; and 3) fatty meals stimulate endocrine L-cells in the GI tract to release PYY into the systemic circulation, producing physiologically active levels of PYY in plasma (3, 4, 19, 28, 34, 44, 53) , and this PYY would be promptly delivered to the kidney via the bloodstream.
The exposure of the kidney to pharmacologically active levels of NPY or PYY may have implications for renovascular structure and health. In this regard, our recent experiments indicate that both NPY and PYY stimulate the proliferation of preglomerular microvascular smooth muscle cells (PGVSMCs) obtained from spontaneously hypertensive rats (SHR) via a mechanism involving activation of Y 1 receptors (26) . In contrast, NPY and PYY exert little or no effect on proliferation of PGVSMCs obtained from normotensive Wistar-Kyoto rats (WKY). Thus, endogenous PP-fold peptides may have adverse effects on renovascular structure in genetic hypertension. However, the reason that NPY and PYY robustly stimulate proliferation of PGVSMCs only in PGVSMCs obtained from genetically susceptible kidneys is unclear. Thus, the focus of the current study was to investigate why SHR, but not WKY, PGVSMCs are responsive to the proliferative effects of NPY and PYY .
Our previously published work demonstrates that Y 1 receptor expression is not different in preglomerular microvessels from SHR vs. WKY (15) , so receptor expression differences are unlikely to account for the differential proliferative responses of SHR vs. WKY to NPY and PYY . On the other hand, our previously published work does show that signaling via G i -linked receptors is enhanced in the renal vasculature of SHR vs. WKY (15) . Inasmuch as Y 1 receptors are G i -coupled receptors, the most likely reason that NPY and PYY stimulate growth more in SHR than WKY PGVSMCs is that postreceptor signaling via the G i pathway is enhanced in SHR PGVSMCs.
Receptor for activated C kinase 1 (RACK1) is a seven-sided propeller protein with seven WD40 repeats, and RACK1 participates in cell signaling by functioning as a scaffolding protein that interacts with G protein ␤␥ subunits, phospholipase C, and PKC (10, 49) and, therefore, organizes and modulates the G i / phospholipase C/PKC pathway. Because Y 1 receptors are coupled to G i (38) and because recent studies from our laboratory indicate that RACK1 participates in proliferation of PGVSMCs (11), we hypothesized that differences in RACK1 levels or distribution, via interacting with the G i /phospholipase C/PKC pathway, may explain why SHR, but not WKY, PGVSMCs are sensitive to the proliferative effects of NPY and PYY .
METHODS

Animals. Studies utilized male SHR and WKY obtained from Taconic Farms (Germantown, NY). The Institutional Animal Care and Use
Committee approved all procedures. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) .
Isolation and culture of PGVSMCs. A complete description of our method for culturing and confirming the identity of rat PGVSMCs can be found in Mokkapatti et al. (39) . All experiments employed cells in 3rd to 5th passage.
Levels of RACK1 in cellular fractions from SHR vs. WKY PGVSMCs.
Membrane, cytosolic, nuclear, and cytoskeletal fractions were isolated from SHR and WKY PGVSMCs using the BioVision FractionPREP Cell Fractionation System Kit (BioVision Research Products, Mountain View, CA). This cell fractionation system has been widely used in a variety of cell types, including vascular and airway smooth muscle cells and renal cells, and reliably separates membrane, cytosolic, nuclear, and cytoskeletal fractions (2, 32, 43, 54 -56) . Briefly, four separate batches (ϳ22.5 million cells per batch) of WKY and SHR PGVSMCs were treated with trypsin and suspended in PBS. The cells were centrifuged, and the supernatant was replaced with cytosol extraction buffer mix containing protease inhibitors, phosphatase inhibitors, and dithiothreitol (DTT). After 20 min, samples were centrifuged, and the supernatant was collected and used as the cytosolic fraction. The pellet was resuspended in membrane extraction buffer-A containing protease inhibitors, phosphatase inhibitors, and DTT and then treated with membrane extraction buffer-B solution. After 1 min, samples were centrifuged, and the supernatant was collected as the membrane fraction. The pellet was resuspended in nuclear extraction buffer mix containing protease inhibitors, phosphatase inhibitors, and DTT, and after 40 min, the samples were centrifuged, and the supernatant was collected as the nuclear fraction. The remaining pellet was dissolved in sample/lysis buffer and collected as the cytoskeletal fraction. Samples were stored at Ϫ80°C until analyzed.
Protein in each sample was determined by the BCA assay (Pierce Biotechnology, Rockford, IL), and then diluted with loading buffer containing ␤-mercaptoethanol, boiled for 10 min, cooled on ice for 5 min, and then centrifuged. SDS-polyacrylamide-gel electrophoresis was performed on each sample (16 g of protein per sample).
Samples were loaded along with Bio-Rad Precision Plus Protein Standard markers (Bio-Rad; Hercules, CA) onto Invitrogen NuPAGE Novex 12% Bis-Tris gels (1.0 mm, 12 wells) (Life Technologies; Carlsbad, CA). Electrophoresis was performed using NuPAGE MOPS SDS running buffer (Life Technologies), and proteins were transferred onto polyvinylidene difluoride membranes in NuPAGE Transfer Buffer (Life Technologies), and membranes were washed briefly in methanol and blocked with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE) and incubated in Odyssey blocking buffer overnight with anti-RACK1 mouse monoclonal antibody (1:400 dilution; Santa Cruz Biotechnology; Santa Cruz, CA; expected size of signal band, 36 kDa) and anti-␤-actin rabbit polyclonal antibody (1:10,000; Santa Cruz Biotechnology). Membranes were washed, incubated in Odyssey blocking buffer for 50 min in the dark at room temperature with IRDye 800CW goat anti-mouse IgG (1:10,000; LI-COR Biosciences), and IRDye 680 goat anti-rabbit IgG (1:10,000; LI-COR Biosciences). Membranes were again washed and placed on filter paper to air dry in the dark. Blots were analyzed using the Odyssey infrared imager (LI-COR Biosciences). For quantitative data analysis, rectangles were placed around the RACK1 (green) and ␤-actin (red) bands, and the integrated intensity values for both red and green channels were determined for each band. Each RACK1 band was normalized to the ␤-actin band. SHR and WKY samples were run on the same gel for each subcellular fraction.
Effect of RACK1 siRNA on cell growth induced by NPY and PYY1-36 in SHR PGVSMCs. SHR PGVSMCs were cultured in DMEM/F12 medium containing 10% FCS, 20 units/ml penicillin, 20 g/ml streptomycin, and 0.05 g/ml amphotericin at 37°C with 5% CO2. One day before transfection, 100,000 cells were plated in 500 l of DMEM/F12 medium containing 2.5% FCS without antibiotics in a 24-well plate. On the day of transfection, 40 pmol of RACK1 siRNA pool or nontargeting siRNA pool (Dharmacon, Lafayette, CO) and 1.5 l of DharmaFECT 1 (Dharmacon) were diluted to 50 l in Opti-MEM I medium and incubated for 5 min at room temperature. Then the diluted siRNA and DharmaFECT 1 were combined and incubated for 20 min at room temperature to allow transfection complexes to form. DMEM/F12 medium containing platelet-derived growth factor-BB (PDGF-BB; 25 ng/ml) without antibiotics was added to the complexes (transfection mixture). In some experiments, the transfection mixture included NPY 1-36 (10 nM) plus sitagliptin (1 M) or PYY1-36 (10 nM) plus sitagliptin (1 M). Sitagliptin was included because PGVSMCs express dipeptidyl peptidase IV (DPPIV), an enzyme that metabolizes and inactivates both NPY and PYY1-36, and sitagliptin, an inhibitor of DPPIV, augments and prolongs the proliferative effects of both NPY and PYY1-36 by blocking their metabolism (26) . The growth medium was removed from the cells and replaced with the transfection mixture, and the cells were incubated with the transfection mixture at 37°C with 5% CO 2. After 72 h, the transfection mixture was replaced with fresh DMEM/F12 medium containing PDGF-BB and other treatments as noted, and at 96 h, cells were dislodged and counted on a Coulter counter. Assessment of siRNA knockdown of RACK1 mRNA. RNA was isolated (TRIzol Reagent; Life Technologies), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). The RACK1 primers were forward, 5=-gtgctcttcgaggtcactcc-3=, reverse, 5=-cggttgtcagaggagaaagc-3=, and 184-bp amplification product. ␤-actin primers were forward, 5=-actcttccagccttccttc-3=, reverse, 5=-atctccttctgcatcctgtc-3=, and 171-bp amplification product. ogy), measured (BCA assay; Pierce) and boiled (5 min in Laemmli buffer). SDS-PAGE was performed on polyacrylamide gels (8 -16%) with 40 g of protein per lane. Proteins were transferred to PDVF membranes. Membranes were blocked in TBS-Tween-20 containing 5% milk and probed with an anti-RACK1 mouse monoclonal primary antibody (1:400; Santa Cruz Biotechnology). Membranes were exposed to horseradish-peroxidase-conjugated-goat anti-mouse antibody (1:4,000; Pierce) and visualized with the Bio-Rad VersaDoc Imaging System using luminal-based enhanced chemiluminescence substrate (Supersignal West Dura Extended Duration Substrate; Pierce).
Cloning of RACK1. The cDNA fragment encoding rat RACK1 was obtained by PCR using rat PGVSMC cDNA as a template with primer set: sense, 5=-ctaagctatccggtgccatc-3=; antisense, 5=-gcgggtaccaatagtcacctg-3=. The RACK1 cDNA was then cloned into pcDNA 3.1/V5-His-TOPO vector by using pcDNA3.1/V5-His TOPO TA expression kit (Life Technologies) as per the manufacturer's instructions. The clone was verified by DNA sequencing.
Effect of RACK1 plasmid on cell growth induced by NPY and PYY1-36 in WKY PGVSMCs. WKY PGVSMCs were cultured in DMEM/F12 medium containing 10% FCS, 20 unit/ml penicillin, 20 g/ml streptomycin, and 0.05 g/ml amphotericin at 37°C with 5% CO 2. On the day of transfection, 100,000 cells were plated in 500 l of growth medium without antibiotics in a 24-well plate so that cells would be 60 -80% confluent. After cells were attached (2 h), 0.45 g of RACK1 plasmid DNA or vector control and 2 l of Plus Reagent (Life Technologies) were diluted to 25 l in Opti-MEM I medium and incubated for 15 min at room temperature. Two microliters of Lipofectamine (Life Technologies) were diluted to 25 l in Opti-MEM I medium. Then, the diluted precomplexed plasmid DNA and diluted Lipofectamine were combined and incubated for 30 min at room temperature to allow transfection complexes to form. The complexes (brought to 250 l with Opti-MEM I) were added into the wells of WKY PGVSMCs, and the cells were incubated for 3.5 h at 37°C with 5% CO 2. An equal volume (250 l) of DMEM/F12 containing 2.5% FCS was added to each well, and the cells were incubated for another 18 h. Next, the transfection complexes were removed and replaced with 500 l of DMEM/F12 containing PDGF-BB (25 ng/ml), and the cells were incubated for another 96 h in the absence or presence of NPY 1-36 (10 nM) plus sitagliptin (1 M) or PYY1-36 (10 nM) plus sitagliptin (1 M). Cells were then dislodged and counted on a Coulter counter. RACK1 protein expression level in the transfected WKY PGVSMCs was evaluated by Western blotting (luminal based enhanced chemiluminescence substrate as described above) using a mouse anti-V5 primary antibody (1:1,000; Life Technologies) and a goat anti-mouse IgG, secondary antibody (1:2,500; Thermo Fisher Scientific, Waltham, MA).
Determination of the effects of inhibitors of the G i/phospholipase C/PKC pathway and downstream signaling molecules on [ 3 H]thymidine incorporation induced by NPY1-36 in SHR PGVSMCs. SHR
PGVSMCs were plated at a density of 5,000 cells per well in 24-well tissue culture dishes and allowed to grow to subconfluence. Cells were growth arrested by feeding DMEM containing 0.4% albumin for 48 h. Next, PGVSMCs were stimulated with DMEM supplemented with PDGF-BB (25 ng/ml) in the presence or absence of various treatments as summarized below. After 20 h of incubation, treatments were repeated with freshly prepared solutions but supplemented with [ 3 H]thymidine (1 Ci/ml). Four hours later, experiments were terminated by washing the cells twice with Dulbecco's PBS and twice with ice-cold trichloroacetic acid (10%). The precipitate was solubilized in 500 l of 0.3 N NaOH and 0.1% sodium dodecylsulfate by incubating at 50°C for 2 h. Samples were mixed with 10 ml scintillation fluid and counted in a liquid scintillation counter. Treatment groups were as follows: No treatment, NPY 1-36 (10 nM), pertussis toxin (100 ng/ml; starting 24 h before the experiment), pertussis toxin (100 ng/ml; starting 24 h before the experiment) ϩ NPY1-36 (10 nM), U73122 (10
, and SB203580 (10 M) ϩ NPY (10 nM) . Cells treated with NPY were also cotreated with sitagliptin (1 M) to block the metabolism and prolong the action of NPY 1-36. Statistical analysis. Data were analyzed either by two-factor analysis of variance (ANOVA; in which case if and only if the interaction term was statistically significant, post hoc tests were performed with a Fisher's LSD test to characterize the nature of the interaction) or by unpaired Student's t-tests. The criterion of significance was P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS
Levels of RACK1 in PGVSMC subcellular compartments.
To determine whether subcellular levels of RACK1 in PGVSMCs differ between SHR vs. WKY, subcellular compartments of SHR and WKY PGVSMCs were fractionated and examined for RACK1 expression. Western blotting for RACK1 revealed signals at 36 kDa in the membrane, cytosolic, nuclear and cytoskeletal fractions of PGVSMCs, indicating the presence of RACK1 in all of these subcellular compartments (Fig. 1A) . The ␤-actin signal was not different between SHR and WKY for any of the subcellular fractions. Importantly, RACK1 levels were significantly greater in both SHR membrane fractions (2.5-fold; P Ͻ 0.0001) and SHR cytoskeletal fractions (1.8-fold; P ϭ 0.0046) compared with the corresponding WKY fractions (Fig. 1, B and C, respectively) ; however, RACK1 levels were similar in the nuclear and cytosolic fractions of SHR vs. WKY PGVSMCs (Fig. 1, D and E, respectively) . Effects of NPY and PYY on cell proliferation in SHR PGVSMCs treated with RACK1 siRNA. To determine whether RACK1 is a critical determinant of the proliferative response to NPY and PYY in SHR PGVSMCs, we next examined whether siRNA knockdown of RACK1 would attenuate the proliferative response to NPY and PYY in SHR PGV SMCs. These experiments were not performed in WKY PGVSMCs, since in these cells, there was no response to either NPY or PYY and, therefore, no response to inhibit. As reported previously in PGVSMCs (11), RACK1 siRNA decreased the expression of both RACK1 mRNA and RACK1 protein (Fig. 2, A and B, respectively) . Two-factor analysis of variance (2F-ANOVA) indicated a significant (P ϭ 0.0044) interaction between RACK1 siRNA and NPY 1-36 (10 nM) on proliferation of SHR PGVSMCs (Fig. 3A) , and post hoc tests indicated that NPY 1-36 increased cell number in SHR PGVSMCs transfected with a nontargeting siRNA (control siRNA) but did not affect cell proliferation in SHR PGVSMCs transfected with targeting RACK1 mRNA. 2F-ANOVA also indicated a significant (P ϭ 0.0328) interaction between RACK1 siRNA and PYY 1-36 (10 nM) on SHR PGVSMC proliferation (Fig. 3B) , and post hoc tests indicated that PYY increased cell number in SHR PGVSMCs transfected with a control siRNA, but it did not affect cell proliferation in PGVSMCs transfected with targeting RACK1 siRNA.
Effects of NPY and PYY on cell proliferation in WKY PGVSMCs transfected with a RACK1 plasmid. If RACK1 participates in the proliferative effects of NPY and PYY in SHR PGVSMCs, and if reduced levels of RACK1 are responsible for the lack of a proliferative response to these peptides in WKY PGVSMCs, then overexpression of RACK1 in WKY PGVSMCs should reproduce the SHR phenotype in WKY PGVSMCs. Western blot analysis confirmed that transfection with RACK1 plasmid was successful in WKY PGVSMCs (Fig. 4) . 2F-ANOVA indicated a significant (P ϭ 0.0160) interaction between RACK1 plasmid and NPY 1-36 (10 nM) on proliferation of WKY PGVSMCs (Fig. 5A) , and post hoc tests indicated that NPY increased cell number in WKY PGVSMCs transfected with RACK1 plasmid but did not affect cell proliferation in WKY PGVSMCs transfected with an empty plasmid (control plasmid). 2F-ANOVA also indicated a significant (P ϭ 0.0157) interaction between RACK1 plasmid and PYY 1-36 (10 nM) on proliferation of WKY PGVSMCs (Fig. 5B) , and post hoc tests indicated that PYY increased cell number in WKY PGVSMCs transfected with RACK1 plasmid but did not affect cell proliferation in WKY PGVSMCs transfected with control plasmid.
Effects of NPY (29); Fig. 6C ] The conclusion that pertussis toxin, U73122 and GF109203X attenuated the ability of NPY 1-36 to increase [ 3 H]thymidine incorporation was supported by the highly significant interaction terms in the 2F-ANOVAs (NPY 1-36 ϫ pertussis toxin, P Ͻ 0.0001; NPY 1-36 ϫ U73122, P ϭ 0.0010; NPY 1-36 ϫ GF109203X, P Ͻ 0.0001). These findings are consistent with the concept that in SHR PGVSMCs RACK1, by organizing the G i /phospholipase C/PKC pathway, participates in the proliferative response to PP-fold peptides.
Effects of NPY (40) . Therefore, we also examined the effects of inhibitors of these signal transduction pathways on the ability of NPY Fig. 7D ]. The conclusion that LY294002, PD98059, rapamycin, and PPI attenuated the ability of NPY 1-36 to increase [ 3 H]thymidine incorporation was supported by the highly significant interaction terms in the 2F-ANOVAs (NPY 1-36 ϫ LY294002, P Ͻ 0.0001; NPY 1-36 ϫ PD98059, P Ͻ 0.0001; NPY 1-36 ϫ rapamycin, P Ͻ 0.0001; NPY 1-36 ϫ PP1, P ϭ 0.0024). These findings are consistent with the concept that RACK1, by organizing the G i /phospholipase C/PKC pathway, participates in the proliferative response to PP-fold peptides via activation of downstream mediators of PKC.
Effects of NPY (Fig. 8, A and B, respectively) , and although Y27623 [10 M; inhibitor of Rho-associated protein kinases (57)] statistically reduced the response to NPY , the attenuation was barely detectable (Fig. 8C) .
DISCUSSION
As demonstrated previously (26) and as confirmed in this study, the Y 1 receptor agonists NPY and PYY 1-36 stimulate proliferation of SHR PGVSMCs yet do not stimulate proliferation of WKY PGVSMCs. In the present study, we focused our attention on the possible role of RACK1 as a cause for the greater effects of Y 1 -receptor activation on proliferation of SHR vs. WKY PGVSMCs. The rationale for this hypothesis was that 1) Y 1 receptors signal via G i (38) ; 2) G i releases ␤␥ subunits (46); 3) ␤␥ subunits are well known to activate phospholipase C (46); 4) the classical effect of phospholipase C is to activate PKC via DAG and calcium (42); 5) the scaffolding protein RACK1 is well known to scaffold and localize/organize all of these signal transduction components [␤␥ subunits, phospholipase C and PKC (10, 49)]; and 6) our previous studies suggest a role for RACK1 in regulating the proliferation of PGVSMCs (11) . The current study corroborates a role for RACK1 with regard to participating in the differential response of SHR vs. WKY PGVSMCs to Y 1 receptor agonists, and this is a novel finding.
We reasoned that increased localization of RACK1 to cell membranes could be involved in the greater response of SHR vs. WKY PGVSMCs to the proliferative effects of Y 1 -receptor activation. This reasoning was based on the concept that activation of phospholipase C by ␤␥ subunits occurs mainly in the membrane domain, and localization of PKC is known to facilitate the bio- logical effects of PKC (42) . Thus, increased localization of RACK1 to cell membranes could be involved in the greater response of SHR vs. WKY PGVSMCs to the proliferative effects of Y 1 -receptor activation. Another reason to entertain the hypothesis that RACK1 localization is important is that our previous study shows that in PGVSMCs, RACK1 binds to the inositol-1,4,5-trisphosphate receptor and enhances the release of calcium from the sarcoplasmic reticulum (11) , and intracellular calcium activates PKC (42) .
A novel finding of the present study is that RACK1 levels in the membrane fraction are 2.5-fold higher in SHR PGVSMCs compared with WKY PGVSMCs. This is in marked contrast to the equal levels of RACK1 in the nuclear and cytosolic fractions of SHR vs. WKY PGVSMCs. Although RACK1 levels are also higher in the cytoskeletal fraction of SHR PGVSMCs, the difference between SHR and WKY PGVSMCs in this regard is not as striking compared with the increased RACK1 levels in the membrane fraction. Therefore, it appears that RACK1 expression in SHR PGVSMCs is increased in precisely the location to most efficiently influence cell proliferation.
Besides using identical amounts of total protein in our Western blot experiments, we also employed ␤-actin as a loading control. Although ␤-actin is well known to exist in the cytosolic and membrane compartments, ␤-actin is also connected to the cytoskeletal compartment (50) and is transported into the nucleus (14) . Therefore, employing ␤-actin as a loading control allows for a uniform method of normalizing protein expression across cell types and between compartments. The levels of ␤-actin did not differ between SHR vs. WKY PGVSMCs, thus indicating that ␤-actin served as a reliable loading control to normalize between strains. Our molecular studies corroborate the hypothesis that RACK1 importantly contributes to the sensitivity of SHR PGVSMCs to the proliferative enhancing effects of Y 1 -receptor activation. In this regard, siRNA-based knockdown of RACK1 abolishes the ability of Y 1 -receptor activation to enhance proliferation. Corresponding experiments were not performed in WKY PGVSMCs because in these cells there was no response to either NPY or PYY and, therefore, no response to inhibit with siRNA knockdown of RACK1.
In the current study, we used a RACK1 plasmid to determine whether overexpression of RACK1 in WKY PGVSMCs could reproduce the SHR phenotype with regard to the proliferative response to Y 1 study are in agreement with this prediction. Blocking the ␤␥/ phospholipase C/PKC pathway at the level of any of these three components significantly attenuates the proproliferative effects of Y 1 -receptor activation in SHR PGVSMCs. Thus, the involvement of the ␤␥/phospholipase C/PKC pathway is entirely consistent with what is known about RACK1 scaffolding. Moreover, blocking some key downstream mediators of PKC also attenuates the proliferative effects of Y 1 -receptor activation in SHR PGVSMCs. Importantly, not all pathway inhibitors were effective in this regard, which suggests that the efficacy of those that were effective was specific. It is important to note that corresponding inhibitor experiments were not performed in WKY PGVSMCs because in these cells, there was no response to NPY and, therefore, no response to inhibit.
Taken together, our results support the model illustrated in Fig. 9 . In SHR PGVSMCs, Y 1 -receptor activation generates the release of ␤␥ subunits from G i proteins and facilitates the activation of the ␤␥/phospholipase C/PKC pathway. Increased localization of RACK1 to membranes in SHR PGVSMCs enhances activation of the ␤␥/phospholipase C/PKC pathway leading to an enhanced proliferative response to Y 1 -receptor activation. Several downstream mediators are also involved, including ERKs, PI3Ks, src family kinases, and mTOR, but not including ROCK, p38 MAPKs, or NADPH oxidases.
What is the reason for the difference in the subcellular distributions of RACK1 between SHR and WKY PGVSMCs? The answer to this question is unknown but worth exploring because the mechanism of differential RACK1 localization could provide insights into the molecular mechanisms of genetic hypertension. In this regard, Liu et al. (33) recently identified Ser-146 in the 4th WD domain of RACK1 as a phosphorylation site that results in dimerization of RACK1 followed by binding of the RACK1 dimer to a number of other proteins (33) . It is conceivable, therefore, that the phosphorylation state of RACK1 determines the localization of RACK1. Another nonmutually exclusive possibility is that some of the binding partners of RACK1 are differentially localized to membranes in SHR PGVSMCs.
Can the findings in the present study be applied to other cell types that participate in the pathophysiology of hypertension, such as smooth muscle cells in different vascular beds or mesangial cells? This is also an important question, and the answer is likely, yes, because recent studies show that RACK1 regulates proliferation of glomerular mesangial cells (11) .
What is the clinical significance of the current findings? DPPIV metabolizes incretin hormones, such as gastric inhibitory polypeptide and glucagon-like peptide-1. Consequently, DPPIV inhibitors raise circulating levels of incretin hormones and, thereby, increase insulin release, which results in sustained reductions in HbA 1c in Type 2 diabetics (5, 21). However, because there are at least 35 peptide substrates for DPPIV (20, 37) , inhibition of DPPIV increases levels of many other biologically active peptides, in addition to incretins, and this may result in long-term consequences. For example, studies by Brown et al. (8) demonstrate that DPPIV inhibitors increase the risk of angioedema in patients treated with angiotensin I-converting enzyme inhibitors, likely because of blockade of substance P metabolism. Because patients with Type 2 diabetes, particular those with the metabolic syndrome, have increased renal sympathetic tone (16, 17) and often ingest fatty meals (18, 36, 45, 47), they likely would have high renal levels of both NPY and PYY . In this regard, although NPY and PYY are potent agonists of Y 1 receptors (6, 38) , DPPIV efficiently converts PYY to PYY and NPY to NPY by cleaving two amino acids from the N-termini of PYY and NPY (35, 37) (Fig. 9) . PYY and NPY are inactive at Y 1 receptors but are selective Y 2 -receptor agonists (6, 38) . Thus, DPPIV inhibitors chronically increase Y 1 -receptor activation. DPPIV inhibitors are becoming widely employed to treat patients with Type 2 diabetes, many of whom have hypertension, vascular disease, and renal diseases as comorbidities. Studies by Kirino et al. (27) show that in DPPIV-deficient rats, more so than in DPPIV-expressing rats, streptozotocin-induced diabetes profoundly and chronically reduces creatinine clearance, and case reports are beginning to link DPPIV inhibitors to renal impairment in patients with Type 2 diabetes (30). These findings suggest that in some patients, DPPIV inhibitors may in the long term adversely influence renal structure and function. The present study suggests that the mechanism by which DPPIV inhibitors adversely affect the kidney may involve the ␤␥/phospholipase C/PKC pathway and that patients with increased membrane localization of RACK1 could be most at risk. Our results also suggest that inhibitors of RACK1 could be useful to prevent adverse renal effects of DPPIV inhibitors, could be antihypertensive, and could prevent or treat hypertension-induced or diabetesinduced nephropathy. Finally, some studies implicate RACK1 in the pathology of cancer (31, 41, 48) , and a recent analysis suggests that patients with hypertension are at increased risk of cancer (51) . It is conceivable, although speculative, that inhibitors of RACK1 could prevent the adverse effects of DPPIV inhibitors, could lower arterial blood pressure, and could decrease the risk of cancer.
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